Gilead to present lenacapavir HIV trial data at AIDS 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Gilead to present lenacapavir HIV trial data at AIDS 2026

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

July 21, 2026 10:00 AM EDT

Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP

Detailed Phase 3 Results from the ISLEND-1 and ISLEND-2 Trials Highlight the Potential of Weekly HIV Treatment with Long-Acting Oral Islatravir/Lenacapavir

Global Access Momentum Continues for Twice-Yearly Lenacapavir for HIV Prevention, Including Discussions in Latin America

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming... More